Corinex Announces $30 Million Investment Led by Energy Growth Momentum, Suma Capital and Adara Ventures to Scale the Deployment of its Grid Flexibility Solutions

Corinex Announces $30 Million Investment Led by Energy Growth Momentum, Suma Capital and Adara Ventures to Scale the Deployment of its Grid Flexibility Solutions

Funding to scale the global deployment of Corinex's broadband over power lines (BPL) grid flexibility and visibility solutions for transformative grid digitalization. VANCOUVER, BC, April 9, 2025 /PRNewswire/ -- Corinex, a global leader in broadband...

Cyient Announces the Launch of Semiconductor Subsidiary

Cyient Announces the Launch of Semiconductor Subsidiary

MUMBAI, India, April 8, 2025 /PRNewswire/ -- Cyient, a leading global engineering and technology solutions company, announced the launch of its fully owned semiconductor subsidiary, Cyient Semiconductors. This strategic move strengthens the...

PRA Group Announces Leadership Succession Plan

PRA Group Announces Leadership Succession Plan

Martin Sjolund appointed President and Chief Executive Officer, effective June 17, 2025 Vikram Atal to serve as senior advisor through December 31, 2025 NORFOLK, Va., April 8, 2025 /PRNewswire/ -- PRA Group, Inc. (Nasdaq: PRAA), a global leader in...

Cellid Announces the Release of "Cellid Precision Fit Lenses" for Next Generation AR Glasses with Diopter Correction

Cellid Announces the Release of "Cellid Precision Fit Lenses" for Next Generation AR Glasses with Diopter Correction

TOKYO, April 7, 2025 /PRNewswire/ -- Cellid Inc., a leading developer of AR display technology and spatial recognition engines, today announced the launch of "Cellid Precision Fit Lenses," a new lens that meets the need for diopter correction...

DOSIsoft PLANET® Onco Dose receives CE MDR Mark and new FDA 510(k) clearance

DOSIsoft PLANET® Onco Dose receives CE MDR Mark and new FDA 510(k) clearance

PARIS, April 7, 2025 /PRNewswire/ -- DOSIsoft, leading provider of patient-specific imaging and dosimetry software solutions for radiation oncology and nuclear medicine, proudly announces the latest release of PLANET® Onco Dose version 3.2 –...

TCTM Announces US$2.0 million Private Placement of Class A Ordinary Shares

TCTM Announces US$2.0 million Private Placement of Class A Ordinary Shares

BEIJING, April 7, 2025 /PRNewswire/ -- TCTM Kids IT Education Inc. (NASDAQ: TCTM) ("TCTM" or the "Company"), a leading provider of IT-focused supplementary STEM education services in China, today announced that it has entered into share purchase...

TCTM Announces Entering into An Intangible Asset Purchase Agreement

TCTM Announces Entering into An Intangible Asset Purchase Agreement

BEIJING, April 7, 2025 /PRNewswire/ -- TCTM Kids IT Education Inc. (NASDAQ: TCTM) ("TCTM" or the "Company"), a leading provider of IT-focused supplementary STEM education services in China, today announced that it has entered into an intangible...

ABL Bio Announces Grabody-B Brain Delivery Platform License Agreement with GSK to Develop Novel Medicines for Neurodegenerative Diseases

ABL Bio Announces Grabody-B Brain Delivery Platform License Agreement with GSK to Develop Novel Medicines for Neurodegenerative Diseases

- ABL Bio and GSK enter into a multi-program agreement to develop novel medicines for neurodegenerative diseases - Programs will leverage ABL Bio's Grabody-B platform technology to effectively deliver molecules a cross the blood-brain barrier - ABL...

Luye Pharma Announces U.S. Launch of ERZOFRI® (paliperidone palmitate) Extended-Release Injectable Suspension for the Treatment of Schizophrenia and Schizoaffective Disorder

Luye Pharma Announces U.S. Launch of ERZOFRI® (paliperidone palmitate) Extended-Release Injectable Suspension for the Treatment of Schizophrenia and Schizoaffective Disorder

PRINCETON, N.J., April 7, 2025 /PRNewswire/ -- Luye Pharma Group today announced that ERZOFRI® (paliperidone palmitate) extended-release injectable suspension is now available for commercial sale in the U.S. for the treatment of adults with...

George Clinical Rebrands as Emerald Clinical Trials

George Clinical Rebrands as Emerald Clinical Trials

New name reflects company's growth and vision to help bring certainty and transparency to global clinical trials SINGAPORE, April 7, 2025 /PRNewswire/ -- George Clinical, a leading clinical research organization (CRO) operating worldwide, is pleased...

  • 1
  • ...
  • 29
  • 30
  • 31
  • 32
  • 33
  • 34
  • 35
  • 36
  • 37
  • ...
  • 102
  • menu
    menu